

Listing of the Claims

The Pending Claims are set forth below:

1. (Previously presented) An immortalized sebocyte derived from a human, characterized in that it exhibits features of a normal, non-transfected and differentiating sebocyte.
2. (Previously presented) The sebocyte according to claim 1, characterized in that it is derived from a human sebaceous gland cell.
3. (Previously presented) The sebocyte according to claim 2, characterized in that the sebaceous gland cell is a facial sebaceous gland cell.
4. (Previously presented) The sebocyte according to claim 1, characterized in that it is present in form of a cell line.
5. (Previously presented) The sebocyte according to claim 1, characterized in that it is immortalized by transfection of DNA.
6. (Previously presented) The sebocyte according to claim 1, characterized in that it expresses a SV-40 large T antigen.
7. (Canceled)
8. (Previously presented) The sebocyte according to claim 1, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

9. (Previously presented) The sebocyte according to claim 1, characterized in that it is cloned.

10. (Original) Human sebocyte cell line DSM ACC2383.

11-22. (Canceled)

23. (Previously presented) The sebocyte according to claim 2, characterized in that it is present in form of a cell line.

24. (Previously presented) The sebocyte according to claim 2, characterized in that it is immortalized by transfection of DNA.

25. (Previously presented) The sebocyte according to claim 2, characterized in that it expresses a SV-40 large T antigen.

26. (Canceled)

27. (Previously presented) The sebocyte according to claim 2, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

28. (Previously presented) The sebocyte according to claim 2, characterized in that it is cloned.

29. (Previously presented) The sebocyte according to claim 3, characterized in that it is present in form of a cell line.

30. (Previously presented) The sebocyte according to claim 3, characterized in that it is immortalized by transfection of DNA.

31. (Previously presented) The sebocyte according to claim 3, characterized in that it expresses a SV-40 large T antigen.
32. (Canceled).
33. (Previously presented) The sebocyte according to claim 3, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.
34. (Previously presented) The sebocyte according to claim 3, characterized in that it is cloned.
35. (Previously presented) The sebocyte according to claim 4, characterized in that it is immortalized by transfection of DNA.
36. (Previously presented) The sebocyte according to claim 4, characterized in that it expresses a SV-40 large T antigen.
37. (Canceled)
38. (Previously presented) The sebocyte according to claim 4, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.
39. (Withdrawn) The sebocyte according to claim 4, characterized in that it is cloned.
40. (Previously presented) The sebocyte according to claim 5, characterized in that it expresses a SV-40 large T antigen.
41. (Canceled)

42. (Previously presented) The sebocyte according to claim 5, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.
43. (Withdrawn) The sebocyte according to claim 4, characterized in that it is cloned.
44. (Canceled)
45. (Previously presented) The sebocyte according to claim 6, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.
46. (Withdrawn) The sebocyte according to claim 4, characterized in that it is cloned.
47. (Canceled)
48. (Withdrawn) The sebocyte according to claim 7, characterized in that it is cloned.
49. (Withdrawn) The sebocyte according to claim 8, characterized in that it is cloned.
50. (Withdrawn) A method of diagnosis, treatment, or cosmetic enhancement, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for a diagnostic, therapeutic or cosmetic purpose.
51. (Withdrawn) A method for examination of physiology or pathophysiology of a human or an animal sebaceous gland, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the examination of the physiology or the pathophysiology of the human or animal sebaceous gland.

52. (Withdrawn) A method for examination of origin of acne and/or seborrhea and/or other disease, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the examination of the origin of acne and/or seborrhea and/or other disease.

53. (Withdrawn) The method according to claim 52, wherein the other disease to be examined is skin disease in which a sebaceous gland function is involved or may be involved.

54. (Withdrawn) A method of for testing of an anti-acne and/or an anti-seborrhea compound or agent, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the testing of the anti-acne and/or the anti-seborrhea compound or agent.

55. (Withdrawn) A method for testing of a compound or an agent against a disease, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the testing of the compound or the agent against the disease.

56. (Withdrawn) The method according to claim 55, wherein the disease is a skin disease in which a sebaceous gland function is involved or may be involved.

57. (Withdrawn) A method for development of a simple or a complex cell culture system, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the development of the simple or the complex cell culture system.

58. (Withdrawn) A method for formation of or for use in a three-dimensional cell aggregation or construction of an organ-type structure, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the formation of or for the use in the three-dimensional cell aggregation or for the construction of the organ-type structure.

59. (Withdrawn) A method for preparation of a cell product, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the preparation of the cell product.

60. (Withdrawn) The method according to claim 59, wherein the cell product is a lipid, a plasmid, a vector, or a protein which is expressed by the cell and/or a DNA or a RNA sequence of the protein.

61. (Withdrawn) A method of using the product obtained according to claim 59 for modification of another cell or modification of an organism, comprising: obtaining the product and using the product to modify the other cell and/or the organism.

62. (Withdrawn) A method of using the product obtained according to claim 60 for modification of another cell or modification of an organism, comprising: obtaining the product and using the product to modify the other cell and/or the organism.

63. (Previously presented) An immortalized sebocyte, wherein the sebocyte expresses one or more antigens selected from the group consisting of: sebaceous gland antigen, human milk fat globulin-1, human milk fat globulin-2, human epithelial sialomucin, Thomsen-

Friedenreich antigen, mucin-type carcinoma-associated antigen, epithelial membrane antigen, Keratin 7, Keratin 13, Keratin 19, and 5 α -reductase of type 1.

64. (Previously presented) The sebocyte of claim 63, wherein the sebocyte expresses sebaceous gland antigen, human milk fat globulin-1, human milk fat globulin-2, human epithelial sialomucin, Thomsen-Friedenreich antigen, mucin-type carcinoma-associated antigen, epithelial membrane antigen, Keratin 7, Keratin 13, Keratin 19, and 5 α -reductase of type 1.

65. (Previously presented) The sebocyte of claim 63, wherein the sebocyte is in the form of a cell line.

66. (Previously presented) An immortalized sebocyte, wherein the sebocyte expresses one or more lipids selected from the group consisting of: squalene, wax ester, triglycerides, cholesterol, cholesterol ester, diglycerides, lanosterol, and free fatty acids.

67. (Previously presented) The sebocyte of claim 66, wherein the sebocyte expresses squalene, wax ester, triglycerides, cholesterol, cholesterol ester, diglycerides, lanosterol, and free fatty acids.

68. (Previously presented) The sebocyte of claim 66, wherein the sebocyte is in the form of a cell line.